Key clinical point: Patients with psoriatic arthritis (PsA) receiving tofacitinib experienced a shorter time to initial clinically meaningful response than those who switched from placebo to tofacitinib.
Major finding: Median time to the initial Health Assessment Questionnaire-Disability Index score response was shorter in patients receiving 5 mg tofacitinib (29-30 days) and 10 mg tofacitinib (53.5 days) than in those switching from placebo to 5 mg tofacitinib (162 days) or 10 mg tofacitinib (112 days; P < .01). The initial Functional Assessment of Chronic Illness Therapy-Fatigue total score response was achieved faster with 5 mg tofacitinib vs. other treatment groups.
Study details: Findings are from a post hoc analysis of 2 phase 3 trials ( OPAL BROADEN and OPAL BEYOND ) including 816 patients with PsA randomly assigned to 5 mg tofacitinib, 10 mg tofacitinib, 40 mg adalimumab, or placebo switching to 5 or 10 mg tofacitinib at month 3.
Disclosures: This study was funded by Pfizer. The authors declared receiving research grants, consulting fees, and honoraria from Pfizer and other sources. Four authors declared being employees and stockholders of Pfizer.
Source: Gladman DD et al. Arthritis Res Ther. 2022;24:40 (Feb 9). Doi: 10.1186/s13075-022-02721-0.